Infinium Pharmachem Past Earnings Performance
Past criteria checks 2/6
Infinium Pharmachem has been growing earnings at an average annual rate of 35.3%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 25% per year. Infinium Pharmachem's return on equity is 19.1%, and it has net margins of 8.3%.
Key information
35.3%
Earnings growth rate
32.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 25.0% |
| Return on equity | 19.1% |
| Net Margin | 8.3% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses Breakdown
How Infinium Pharmachem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,356 | 113 | 66 | 0 |
| 31 Dec 23 | 1,160 | 107 | 59 | 0 |
| 30 Sep 23 | 964 | 102 | 56 | 0 |
| 30 Jun 23 | 1,053 | 98 | 57 | 0 |
| 31 Mar 23 | 1,142 | 95 | 58 | 0 |
| 31 Mar 22 | 991 | 61 | 39 | 0 |
| 31 Mar 21 | 548 | 27 | 24 | 0 |
| 31 Mar 20 | 364 | 10 | 21 | 0 |
| 31 Mar 19 | 181 | 4 | 13 | 0 |
Quality Earnings: INFINIUM has a high level of non-cash earnings.
Growing Profit Margin: INFINIUM's current net profit margins (8.3%) are higher than last year (8.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INFINIUM's earnings have grown significantly by 35.3% per year over the past 5 years.
Accelerating Growth: INFINIUM's earnings growth over the past year (19.1%) is below its 5-year average (35.3% per year).
Earnings vs Industry: INFINIUM earnings growth over the past year (19.1%) did not outperform the Pharmaceuticals industry 19.2%.
Return on Equity
High ROE: INFINIUM's Return on Equity (19.1%) is considered low.